UL 11 5 2000 A

PTO/SB/08A (08-00)
Approaction use through 10/31/2002. OMB 0651-0031
J.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it contains a valid OMB control numb

Subat	itute for form 1449/	A/DTO	EL	C mplete if Known			
Subst	itule for form 1449/	WF10	TRADE	Application Number	(NOT YET ASSIGNED)		
INF	ORMATIO	N DIS	CLOSURE	Filing Date	July 5, 2001		
ST	ATEMENT	BY AF	PPLICANT	First Named Inventor	Yoichi FUJII		
4	ıse as many sl	hooto on	nococcond	Group Art Unit	1648		
(L	ise as many si	ieeis as	necessary)	Examiner Name	U. Winkler		
Sheet	1	of	2	Attorney Docket Number	NZK-128-1		

			U.S	S. PATENT DOCUMENTS		
Examiner Initials*		U.S. Pate	ent Document		Date of Publication	Pages, Columns, Lines,
	Cite No. ¹	Number Kind Code ² (if known)		Name of Patentee or Applicant of Cited Document	of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear
W		4,816,	397	Michael A. BOSS et al.	Mar. 28, 1989	
1		4,816,	567	Shmuel CABILLY et al.	Mar. 28, 1989	
<u> </u>		5,225,	539	Gregory Paul WINTER	July 6, 1993	
					1	

				FORE	IGN PATENT DOCUMEN	TS		
Examiner Initials*	Cite	.			Name of Patentee or	Date of Publication	Pages, Columns, Lines, Where Relevant	
	No. ¹	Office	e ³ Number	Kind Code⁵ (if known)	Applicant of Cited Document	of Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T ⁶
TIL)		EP	0 120 694 B1		Celitech Limited	Oct. 3, 1984		
\		EP	0 125 023 B1		Genentech, Inc.	Nov. 14, 1984		
		EP	0 239 400 A2		Gregory Paul WINTER	Sept. 30, 1987		
		wo	86/01533		Celitech Limited	Mar. 13, 1986		
		wo	98 13377		Biomolecular Research Institute Ltd.	Apr. 2, 1998		
		FR	2 720 068		Institut National de la Sante et de la Recherche Medicale	Nov. 24, 1995		
4		JP	04360838		Sanyo Kokusaku Pulp Co., Ltd.	Dec. 14, 1992		
		1						

	<i>]</i>		_			
Examiner Signature	U1	$_{\mathbf{A}}Nn$		Date Considered	M25/02	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement:: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside) inside th	(+)	sian (sula	а	type	Please
------------------------------------	-------------	-----	--------	------	---	------	--------

+]

Appro

For use through 10/31/2002. OMB 0651-0031

PTO/SB/08A (08-00)

Spersons are required to respond to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995, Complete if Kn wn Substitute for form 1449A/PTO Application Number (NOT YET ASSIGNED) INFORMATION DISCLOSURE Filing Date July 5, 2001 Yoichi FUJII STATEMENT BY APPLICANT First Named Inventor **Group Art Unit** 1648 (use as many sheets as necessary) U. Winkler **Examiner Name Attorney Docket Number** NZK-128-1 Sheet 2 of 2

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
llw		FUJII, Y., ET AL., "Biological Overview of HIV Accessory Protein Nef," <u>Saibo Kogaku</u> , 1997, pp. 94-99, vol. 16, no. 1	_
		LIU ET AL., "Binding of HIV-1 Nef to a novel thioesterase enzyme correlates with Nef-mediated CD4 down-regulation", The Journal of biological Chemistry, 1997, pp. 13779-13785, Vol. 272	
		CAWTHON ET AL., "cDNA sequence and genomic structure of EV12B, a gene lying within an intron of the neurofibromtosis type 1 gene", Genomics, 1991, pp. 446-460, Vol. 9	
		AHN ET AL., "The structural and functional diversity of dystophin", Nature Genetics, 1993, pp. 283-291, Vol. 3	
		OKADA, H., ET AL., "Inhibition of HIV-1 Nef induced apoptosis of uninfected human blood cells by serine/threonine protein kinase inhibitors, fasudil hydrochloride and M3", FEBS LETTERS, 2-6-98, PPS. 363-367, Vol. 422, No. 3, XP002115665, Amsterdam, NL	
		LUO T., ET AL., "Infectivity enhancement by immunodeficiency virus type 1 Nef is independent of its association with a cellular serine/threonine kinase", <u>Journal of Virology</u> , 1997, pp. 9524-9530, Vol. 71, No. 12, XP002115666, US	
		ROSSI, F., ET AL., "H _s N3 proteasomal subunit as a target for human immunodeficiency virus type 1 Nef protein", <u>Virology</u> , 1997, pp. 33-45, Vol. 237, No. 1, XP002115667, Orlando, US	
		SMITH, B.L., ET AL., "The HIV Nef protein associates with protein kinase C theta", <u>Journal of Biological Chemistry</u> , 1996, pp. 16753-16757, Vol. 271, No. 28, XP002115668, MD, US	
b		DE REUCK, ET AL., "A double-blind study of neurotropin in patients with acute ischemic stroke," Acta Neurol Scand, 1994, pp. 329-335, 89	

Examiner Date Considered Signature

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement:: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEÉS OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.